Published On: Wed, Feb 26th, 2020

Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals

Tagged with: | | | | |

is set to launch its drug KALYDECO (ivacaftor) in , which will be available to eligible patients from next month.

The US biopharma company said that clinicians can apply for patient access using the exceptional circumstances framework under the Pharmaceutical Management Agency (PHARMAC).

– Senior Vice President of Vertex International said: “Today is an important day for the CF community in New Zealand. For the first time in New Zealand CF patients will have access to a medicine that treats the underlying cause of their disease. We appreciate the engagement and collaboration from PHARMAC, and other involved parties, to bring this important medicine to patients.”

According to Vertex Pharmaceuticals, its cystic fibrosis are reimbursed in 20 plus countries, which includes , France, Germany, Ireland, Sweden, Italy, , the UK, and the US.

Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals

Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals. Photo courtesy of Free-Photos from Pixabay.

Related posts